Compare Stocks: XLO, WHWK, CGEN, and ALXO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.39 +6.1%	$1.92	$1.05 ▼ $2.66	$181.14M	0.39	1.00 million shs	1.96 million shs
CGEN Compugen	$2.33 -2.1%	$2.46	$1.38 ▼ $3.23	$225.04M	2.78	173,028 shs	94,071 shs
WHWK Whitehawk Therapeutics	$3.76 +0.5%	$4.30	$1.82 ▼ $5.49	$213.21M	0.81	339,388 shs	277,923 shs
XLO Xilio Therapeutics	$9.05 +0.1%	$9.04	$6.47 ▼ $12.74	$59.49M	-0.14	10,588 shs	11,128 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	-22.94%	-34.50%	-40.45%	-29.95%
CGEN Compugen	0.00%	-4.42%	-8.46%	+10.19%	+72.46%
WHWK Whitehawk Therapeutics	0.00%	-10.95%	-19.05%	-15.19%	+92.78%
XLO Xilio Therapeutics	0.00%	-0.99%	+0.44%	-2.48%	-18.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.39 +6.1%	$1.92	$1.05 ▼ $2.66	$181.14M	0.39	1.00 million shs	1.96 million shs
CGEN Compugen	$2.33 -2.1%	$2.46	$1.38 ▼ $3.23	$225.04M	2.78	173,028 shs	94,071 shs
WHWK Whitehawk Therapeutics	$3.76 +0.5%	$4.30	$1.82 ▼ $5.49	$213.21M	0.81	339,388 shs	277,923 shs
XLO Xilio Therapeutics	$9.05 +0.1%	$9.04	$6.47 ▼ $12.74	$59.49M	-0.14	10,588 shs	11,128 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	0.00%	-22.94%	-34.50%	-40.45%	-29.95%
CGEN Compugen	0.00%	-4.42%	-8.46%	+10.19%	+72.46%
WHWK Whitehawk Therapeutics	0.00%	-10.95%	-19.05%	-15.19%	+92.78%
XLO Xilio Therapeutics	0.00%	-0.99%	+0.44%	-2.48%	-18.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	230.94% Upside
CGEN Compugen	3.00	Buy	$5.00	114.59% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	118.09% Upside
XLO Xilio Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XLO, WHWK, CGEN, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/18/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/2/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/4/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	CGEN Compugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
CGEN Compugen	$72.76M	3.03	$0.37 per share	6.37	$1.09 per share	2.14
WHWK Whitehawk Therapeutics	$7.14M	30.02	N/A	N/A	$2.89 per share	1.30
XLO Xilio Therapeutics	$43.77M	1.36	N/A	N/A	$7.31 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
CGEN Compugen	$35.34M	$0.38	6.13	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/5/2026 (Estimated)

Latest XLO, WHWK, CGEN, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
CGEN Compugen	N/A	5.72	5.72
WHWK Whitehawk Therapeutics	N/A	17.38	17.38
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
CGEN Compugen	12.22%
WHWK Whitehawk Therapeutics	52.08%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
CGEN Compugen	9.50%
WHWK Whitehawk Therapeutics	49.90%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
CGEN Compugen	75	94.55 million	85.57 million	Optionable
WHWK Whitehawk Therapeutics	23	57.01 million	28.56 million	N/A
XLO Xilio Therapeutics	76	6.58 million	6.09 million	Not Optionable

XLO, WHWK, CGEN, and ALXO Headlines

Recent News About These Companies

Xilio Names Yariv Houvras Chief Medical Officer

September 28 at 3:19 PM | rttnews.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

September 28 at 10:19 AM | markets.businessinsider.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D.

September 28 at 7:30 AM | globenewswire.com

Reviewing Xilio Therapeutics (NASDAQ:XLO) and Rigel Pharmaceuticals (NASDAQ:RIGL)

September 20, 2026 | americanbankingnews.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

May 12, 2026 | zacks.com

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2026 | globenewswire.com

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40

April 28, 2026 | msn.com

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

April 17, 2026 | globenewswire.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors

April 16, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

April 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, WHWK, CGEN, and ALXO Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.39 +0.08 (+6.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.37 -0.02 (-1.51%)

As of 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Compugen NASDAQ:CGEN

$2.33 -0.05 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.00 (+0.21%)

As of 07:30 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Whitehawk Therapeutics NASDAQ:WHWK

$3.76 +0.02 (+0.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.76 0.00 (-0.13%)

As of 07:40 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Xilio Therapeutics NASDAQ:XLO

$9.05 +0.01 (+0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$9.05 0.00 (0.00%)

As of 07:30 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, WHWK, CGEN, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, WHWK, CGEN, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, WHWK, CGEN, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, WHWK, CGEN, and ALXO Company Descriptions

ALX Oncology NASDAQ:ALXO

Compugen NASDAQ:CGEN

Whitehawk Therapeutics NASDAQ:WHWK

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLO, WHWK, CGEN, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLO, WHWK, CGEN, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLO, WHWK, CGEN, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO, WHWK, CGEN, and ALXO Company Descriptions

ALX Oncology NASDAQ:ALXO

Compugen NASDAQ:CGEN

Whitehawk Therapeutics NASDAQ:WHWK

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools